Insight Molecular Diagnostic (IMDX) traded up 6.01 % during a 24 hours period ending at 10:15 AM Central Europe on Tuesday 27th. One Insight Molecular Diagnostic stock can currently be bought for about USD 3 on popular exchanges. Current supply of Insight Molecular Diagnostic stocks is 31.9 mn. Insight Molecular Diagnostic has a current market capitalization of USD 92 mn and approximately USD 480 k worth of Insight Molecular Diagnostic was traded on exchanges in the last 24 hours. Since last month end, Insight Molecular Diagnostic has traded -5.66 % down. Simple moving average of last 200 days is at USD 4.82. The highest price of past 52 weeks was recorded at USD 8.51 on 11/12/2025. 52 weeks low was at USD 2.42 on 03/31/2026.
Here is how related stocks have performed in the past 24 hours:
Seer (SEER) traded down -2.03 % and now trades at USD 1.93. Current market capitalisation for Seer is USD 110.2 mn.
Soundthinking (SSTI) traded flat 0 % and now trades at USD 8.36. Soundthinking has a market capitalisation of USD 110.3 mn.
Minerva Neurosciences (NERV) traded down -4.35 % and now trades at USD 2.2. Minerva Neurosciences has a market capitalisation of USD 108.4 mn.
Cibus (CBUS) traded down -1.06 % and now trades at USD 1.4. Current market capitalisation for Cibus is USD 107.8 mn.
Voyager Therapeutics (VYGR) traded up 0.57 % and now trades at USD 1.75. Voyager Therapeutics has a market capitalisation of USD 108.1 mn.
About Insight Molecular Diagnostic
The Oncocyte Corporation serves as a molecular diagnostics company, operating within the health care sector and specializing in biotechnology. The company offers actionable answers at critical stages across the cancer care continuum, aiming to improve patient outcomes by expediting and optimizing diagnosis and treatment. Oncocyte Corp operates in the United States, accessible through its website at www.oncocyte.com and traded on the Nasdaq stock exchange.